<DOC>
	<DOCNO>NCT01303055</DOCNO>
	<brief_summary>It report pancreatic beta cell function already decline pre-diabetic stage , impair glucose tolerance ( IGT ) . It clarify whether inhibitor dipeptidyl peptidase IV enzyme ( DPP-IV inhibitor ) improve beta cell function human pancreas , however , efficacy ensure , may become first medicine chosen treatment type 2 diabetes IGT . In trial , DPP-IV inhibitor , Alogliptin , Metformin give diabetic patient whose HbA1c level 7.9 % . Oral glucose tolerance test ( OGTT ) conduct , year , two year begin trial beta cell function evaluate .</brief_summary>
	<brief_title>Effects Alogliptin Pancreatic Beta Cell Function</brief_title>
	<detailed_description>Patients randomly allocate two group . They receive either Alogliptin Metformin . Alogliptin : The investigator start 25 mg QD dose maintain . Metformin : The investigator start 250 mg QD dose slowly increase 750 mg TID . The dose increase possible maximum , 2250 mg , HbA1c maintain 6.9 % . However , increase dose elder patient require careful consideration . Participants take part study receive dietary exercise coaching . Participation study expect last 2 year . Patients terminate trial HbA1c exceed 8.4 % three month . The investigator evaluate beta cell function conduct 75 g OGTT , year , two year begin trial . Alogliptin Metformin stop three day OGTT . The investigator make sure urine ketone negative oral glucose load .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients diagnose type 2 diabetes HbA1c level 7.9 % n't receive oral hypoglycemic agent insulin treatment past three month . Patients whose 75 g OGTT 30minutes insulin secretion exceed 100 μU/ml Patients renal failure serum creatinine level ≧ 1.2 Patients hepatocirrhosis Patients proliferative diabetic retinopathy bad Patients acute infectious disease Patients treat steroids Patients cancer Pregnant patient Patients malfunction heart ( NYHA classification IIIIV ) Patients decide inappropriate subject study physician</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Pancreatic beta Cell</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Metformin</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>hemoglobin A1c protein , human</keyword>
	<keyword>Oral Glucose Tolerance Test</keyword>
</DOC>